Red Abbey Venture Partners

Perceiv AI specializes in precision medicine using advanced machine learning algorithms. It helps pharmaceutical companies enhance clinical trial success by identifying suitable patient subpopulations for complex diseases, such as Alzheimer's and cardiovascular conditions.

Cohero Health, Inc. is a digital respiratory health company that focuses on developing solutions for the management of asthma and chronic obstructive pulmonary disease. The firm offers a connected health platform that includes the BreatheSmart app, which provides personalized reminders for medication adherence, tracks inhaler usage, measures lung function, and monitors symptoms and environmental conditions. Cohero Health also supplies mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker for both control and rescue medications. Additionally, the company offers BreatheSmart Connect, a Software-as-a-Service solution that facilitates remote monitoring and communication between patients and healthcare providers. Founded in 2012 and headquartered in New York, Cohero Health operates as a subsidiary of AptarGroup, Inc.

Atopix Therapeutics Limited is a clinical-stage biopharmaceutical company based in Oxford, United Kingdom, focused on developing innovative anti-inflammatory medicines for the treatment of asthma, chronic allergic conditions, and other atopic diseases. Founded in 2012, the company specializes in a novel class of oral anti-allergic medications known as CRTH2 antagonists. Its lead candidate is currently undergoing a Phase 2 clinical trial aimed at addressing moderate to severe atopic dermatitis, with studies being conducted at several prominent dermatology centers across Europe. Atopix Therapeutics operates as a subsidiary of Chiesi Farmaceutici S.p.A.

Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.

Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

Corridor Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutic small molecule inhibitors of arginase. Its arginase is an enzyme that competes with endothelial nitric oxide synthase for the use of the common substrate l-arginine. The company's arginase also leads to the production of ornithine which increases polyamine, stimulating cell division, and contributing to hyperplasia and fibrosis. Corridor Pharmaceuticals, Inc. was formerly known as Arginetix, Inc. and changed its name to Corridor Pharmaceuticals, Inc. on June 17, 2010. The company was founded in 2007 and is based in Lutherville, Maryland.

MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment. Its pipeline includes Margetuximab targeting HER2-expressing tumors, Flotetuzumab for acute myeloid leukemia, and other immuno-oncology product candidates such as MGA012, MGD013, MGD019, and Enoblituzumab. The company also develops combination therapies like MGD009 with MGA012, and antibody drug conjugates like MGC018 targeting B7-H3.

Stromedix is a biotechnology company dedicated to developing innovative therapies for chronic organ failure, particularly focusing on fibrosis. The company's expertise lies in remodeling tissues to address the underlying mechanisms of these conditions. While its initial focus is on chronic indications, Stromedix aims to expand its therapeutic pipeline into related areas, including acute organ failure and cancer, leveraging its scientific knowledge and technological capabilities to create impactful treatments.

Advanced BioHealing is an industry leader in the science of regenerative medicine. The Company is focused on the commercialization of cell-based and tissue-engineered products. It currently markets the FDA-approved product Dermagraft®, for diabetic foot ulcers. Additionally, the Company's development pipeline includes a next-generation bioengineered tissue product which is in clinical trials. ABH is a privately held company with research & development offices in New York, NY and manufacturing operations in La Jolla, CA.

Kémia operates as a pharmaceutical company. The company discovers and develops small molecule therapeutics. It offers allosteric kinase inhibitors for the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as for cardiovascular and metabolic conditions; and modulators of G protein-coupled receptors. The company specializes in the fields of medicinal and analytical chemistry, biology, pharmacology, pharmacokinetics, pharmacodynamics, and clinical development.

CoGenesys is a biopharmaceutical company dedicated to the development of peptide- and protein-based therapeutics. It focuses on creating innovative medicines to address a range of diseases, including cancer, cardiovascular, metabolic, infectious, autoimmune, and central nervous system disorders. The company conducts clinical trials to establish the safety and efficacy of its compounds, and subsequently pursues selective licensing or partnerships to secure funding for further development of its products.

MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment. Its pipeline includes Margetuximab targeting HER2-expressing tumors, Flotetuzumab for acute myeloid leukemia, and other immuno-oncology product candidates such as MGA012, MGD013, MGD019, and Enoblituzumab. The company also develops combination therapies like MGD009 with MGA012, and antibody drug conjugates like MGC018 targeting B7-H3.

[Sirtris Pharmaceuticals](http://www.sirtrispharma.com) (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. via: [Sirtris](http://www.sirtrispharma.com)

Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that target muscle function. The company focuses on developing muscle activators and inhibitors for conditions characterized by reduced muscle performance, weakness, and fatigue, including diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. Utilizing small molecules specifically engineered to enhance muscle function and contractility, Cytokinetics aims to create investigational medicines that may improve the health span of individuals affected by serious cardiovascular and neuromuscular disorders.

Nereus Pharmaceuticals, Inc. engages in the discovery and development of therapeutics for the treatment of oncology, infectious diseases, and inflammation. The company uses its marine microbiology technologies for the discovery and development of drug candidates. Its oncology drug candidates include NPI-2358, a tumor vascular disrupting agent for the treatment of solid tumors; and NPI-0052, a proteasome inhibitor for the treatment of solid tumors, lymphomas, and multiple myeloma. The company was founded in 1998 and is based in San Diego, California.

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland, specializing in the discovery and development of therapeutics for autoimmune and inflammatory diseases. The company’s innovative approach revolves around modifying epithelial permeability through compounds that regulate tight junctions in cellular barriers, addressing conditions related to autoimmunity. Alba's research targets a variety of disorders, including celiac disease, asthma, chronic obstructive pulmonary disease (COPD), and acute lung injury, as well as other immune-mediated and inflammatory diseases. The company's focus extends to therapeutic areas such as type 1 diabetes, inflammatory bowel disease (IBD), mucosal vaccines, and drug delivery systems, aiming to improve treatment outcomes for patients suffering from diverse health challenges.

Oxagen Limited is a biopharmaceutical company based in London, United Kingdom, focused on developing and commercializing anti-inflammatory medicines to treat asthma and other chronic allergic conditions. The company specializes in small molecule drugs that target the CRTH2 receptor, which plays a key role in initiating and maintaining allergic responses. Oxagen's pipeline includes OC000459, an oral CRTH2 antagonist designed for eosinophilic asthma and allergic rhinoconjunctivitis. Additionally, the company addresses various inflammatory diseases such as autoimmune disease, inflammatory bowel disease, psoriasis, allergy, and rheumatoid arthritis. Founded in 1996, Oxagen serves customers globally, including in the United Kingdom, Russia, CIS countries, and other international markets.

Anacor Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of small-molecule therapeutics based on its unique boron chemistry platform. The company is known for its marketed product, KERYDIN, a topical solution for treating onychomycosis, a fungal infection of the toenails. Anacor's lead product candidate, crisaborole topical ointment, is an anti-inflammatory therapy currently undergoing Phase III clinical trials for mild-to-moderate atopic dermatitis and psoriasis. Additionally, the company is developing AN3365, an antibiotic aimed at treating infections caused by Gram-negative bacteria. Anacor has established collaboration agreements with various organizations to advance drug candidates targeting diseases such as African trypanosomiasis, tuberculosis, and other neglected tropical diseases. Founded in 2000 and headquartered in Palo Alto, California, Anacor Pharmaceuticals was previously known as AnaMax, Inc. and became a subsidiary of Pfizer Inc. in 2016.

MacroGenics is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for cancer treatment. Its pipeline includes Margetuximab targeting HER2-expressing tumors, Flotetuzumab for acute myeloid leukemia, and other immuno-oncology product candidates such as MGA012, MGD013, MGD019, and Enoblituzumab. The company also develops combination therapies like MGD009 with MGA012, and antibody drug conjugates like MGC018 targeting B7-H3.